Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6099701 | Journal of Crohn's and Colitis | 2013 | 10 Pages |
Abstract
Adalimumab therapy significantly improved work productivity and disease-specific quality of life for patients with moderate to severe Crohn's disease. Patients who failed prior infliximab therapy and patients naïve to infliximab benefited from adalimumab, with potentially greater benefits for infliximab-naïve patients (NCT00409617).
Keywords
HBIShort Inflammatory Bowel Disease QuestionnaireTNFSIBDQEIMSPNRMCIDAdalimumabHRQOLTAICareWork productivityCrohn's diseaseextraintestinal manifestationsMinimum clinically important differenceHarvey Bradshaw indexAnti-Tumor Necrosis Factortumor necrosis factorpatient-reported outcomePROIndirect costsC-reactive proteinCRPHealth-related quality of life
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Edouard Louis, Robert Löfberg, Walter Reinisch, Anne Camez, Mei Yang, Paul F. Pollack, Naijun Chen, Jingdong Chao, Parvez M. Mulani,